MRVI vs AAPG
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MRVI · Maravai LifeSciences$6.98 ▼ 2.92%
AAPG · Ascentage Pharma$11.97 ▼ 3.78%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MRVI +89.7%
- AAPG -62.6%
Head to head
| Metric | MRVI | AAPG |
|---|---|---|
| Price | $6.98 | $11.97 |
| Change today | ▼ 2.92% | ▼ 3.78% |
| Market cap | $1.04B | $1.12B |
| Return, 3 months | -17.2% | -28.4% |
| Return, year to date | +114.8% | -54.4% |
| Return, 1 year | +86.1% | -60.9% |
| P/E (TTM) | – | – |
| P/B | 5.3 | 13.4 |
| P/E percentile vs own 5y | 0th | 98th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +10.1% | -41.5% |
| Net profit growth (YoY) | +46.7% | -206.4% |
| Gross margin | 39.1% | 93.9% |
| Operating margin | -25.6% | -216.7% |
| Net margin | -30.8% | -228.5% |
| Return on equity | -29.8% | -240.3% |
| Analyst target vs. price | +41.5% | +250.9% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 43 | 29 |
| 30-day volatility | 80.7% | 64.7% |
| Max drawdown, 1 year | -29.6% | -65.1% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AAPG is the largest of the group by market value.
- MRVI has returned the most over the past year.
- MRVI is growing revenue fastest.
- MRVI keeps the most profit per dollar of sales.
- AAPG has been the calmest stock over the last 30 days.